Annette Langer-Gould to Adult
This is a "connection" page, showing publications Annette Langer-Gould has written about Adult.
Connection Strength
2.368
-
Anti-NMDA receptor encephalitis outcomes in a population-based cohort. J Neurol. 2026 Jul 15; 273(8).
Score: 0.105
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
Score: 0.102
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
Score: 0.101
-
Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025 May 27; 104(10):e213607.
Score: 0.096
-
Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility. Mult Scler. 2025 Apr; 31(5):539-547.
Score: 0.095
-
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200255.
Score: 0.090
-
Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
Score: 0.086
-
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
Score: 0.084
-
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
Score: 0.078
-
Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
Score: 0.072
-
An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis. Mult Scler. 2021 09; 27(10):1611-1614.
Score: 0.072
-
Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.068
-
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020 05 05; 94(18):e1939-e1949.
Score: 0.068
-
Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
Score: 0.067
-
Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun; 25(3):773-792.
Score: 0.064
-
MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. Nutrients. 2018 Feb 27; 10(3).
Score: 0.059
-
Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis. Nutrients. 2018 Feb 07; 10(2).
Score: 0.058
-
Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study. Neurology. 2017 Sep 26; 89(13):1330-1337.
Score: 0.057
-
Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurology. 2017 Aug 08; 89(6):563-569.
Score: 0.056
-
Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. PLoS One. 2016; 11(3):e0149094.
Score: 0.051
-
Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol. 2015 Oct; 72(10):1132-8.
Score: 0.050
-
Place of birth,age of immigration,and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord. 2015 Jan; 4(1):25-30.
Score: 0.047
-
Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec; 71(12):1506-13.
Score: 0.047
-
The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Oct 28; 83(18):1685.
Score: 0.046
-
The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol. 2014 Jul; 261(7):1349-55.
Score: 0.045
-
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
Score: 0.044
-
Spinal cord lesions and disability in Hispanics with multiple sclerosis. J Neurol. 2013 Nov; 260(11):2770-6.
Score: 0.043
-
Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
Score: 0.042
-
Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012 Dec; 259(12):2565-70.
Score: 0.039
-
Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses. Arch Neurol. 2011 Mar; 68(3):310-3.
Score: 0.035
-
Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010 Jul; 16(7):855-61.
Score: 0.034
-
Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis. Arch Neurol. 2010 Jan; 67(1):51-7.
Score: 0.033
-
Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
Score: 0.032
-
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
Score: 0.027
-
What went wrong in the natalizumab trials? Lancet. 2006 Mar 04; 367(9512):708-10.
Score: 0.025
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81.
Score: 0.024
-
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023 07 01; 80(7):693-701.
Score: 0.021
-
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
Score: 0.019
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Score: 0.018
-
Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.017
-
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
Score: 0.017
-
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
Score: 0.017
-
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
Score: 0.017
-
The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 03 05; 92(10):e1029-e1040.
Score: 0.016
-
Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
Score: 0.016
-
Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016 05; 22(6):801-9.
Score: 0.013
-
Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016 05; 22(6):810-6.
Score: 0.013
-
Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014 Jul 01; 71(7):891-5.
Score: 0.011
-
Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014 Jun; 34(6):435-40.
Score: 0.011
-
Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16(3):37-41.
Score: 0.010
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
Score: 0.007
-
Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003 Nov-Dec; 24(10):1941-5.
Score: 0.005